---
title: "Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to Astellas"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290566477.md"
description: "Sangamo Therapeutics, in Chapter 11 bankruptcy, signed stalking horse asset purchase agreements for court-supervised sales. Eli Lilly agreed to buy core technology platforms for $50 million plus assumed liabilities, while Astellas will acquire the Fabry disease program for $25 million upfront and up to $25 million in milestones. Both deals require Bankruptcy Court approval under Section 363 and are subject to higher bids."
datetime: "2026-06-23T12:53:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290566477.md)
  - [en](https://longbridge.com/en/news/290566477.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290566477.md)
generator: "portal-rs"
---

# Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to Astellas

Sangamo Therapeutics entered Chapter 11 and signed two stalking horse asset purchase agreements to advance court-supervised sales. Eli Lilly agreed to acquire Sangamo’s core technology platforms and related rights for $50 million plus assumed liabilities, while Astellas agreed to purchase the Fabry disease program for $25 million upfront and up to $25 million in milestones. Both transactions are subject to higher or better bids and require Bankruptcy Court approval under Section 363. The company aims to maximize value for stakeholders through these proposed sales.

**Agreement 1: Sangamo Therapeutics Sets $50 Million Stalking Horse Sale of Platform Assets to Eli Lilly**

-   **Agreement type**: Stalking horse asset purchase agreement (sale of technology platforms and IP)
-   **Counterparty**: Eli Lilly
-   **Signed / Effective**: Jun 22 2026 / same
-   **Duration / Termination**: N/A
-   **Reason**: Pursue Section 363 sales to maximize stakeholder value

**Agreement 2: Sangamo Therapeutics Lines Up Up to $50 Million Stalking Horse Sale of Fabry Program to Astellas**

-   **Agreement type**: Stalking horse asset purchase agreement (Fabry program sale)
-   **Counterparty**: Astellas
-   **SIGNED / Effective**: Jun 22 2026 / same
-   **Duration / Termination**: N/A
-   **Reason**: Pursue Section 363 sales to maximize stakeholder value

Original SEC Filing: SANGAMO THERAPEUTICS, INC \[ SGMO \] - 8-K - Jun. 23, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SGMO.US](https://longbridge.com/en/quote/SGMO.US.md)
- [ALPMY.US](https://longbridge.com/en/quote/ALPMY.US.md)
- [4503.JP](https://longbridge.com/en/quote/4503.JP.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [SGMOQ.US](https://longbridge.com/en/quote/SGMOQ.US.md)

## Related News & Research

- [How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems (VEEV) Has Changed Its Investment Story](https://longbridge.com/en/news/296430987.md)
- [Why Is Omniab Stock Rallying After Eli Lilly Deal?](https://longbridge.com/en/news/296113651.md)
- [Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient](https://longbridge.com/en/news/296005917.md)
- [Elyxium Wealth LLC Has $7.30 Million Position in Eli Lilly and Company $LLY](https://longbridge.com/en/news/296017075.md)
- [LLY Stock Alert: What to Know as Eli Lilly Teams Up With CVS on Weight-Loss Drugs](https://longbridge.com/en/news/295005008.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**